For instance, the KEYNOTE-012 trial, which evaluated pembrolizumab in advanced HNSCC patients, showed that a subset of patients with high PD-L1 expression experienced clinical benefit, indicating that PD-1 inhibitors could potentially be effective in tumors like OCS, which may have similar immune evasion mechanisms (48). Here, CD274 is linked to head and neck squamous cell carcinoma.